Fig. 1 · Structure

Cat. No.: A10214
CAS No.: 113852-37-2
Formula: C₈H₁₄N₃O₆P
Mol. Weight: 279.2

Documents & Downloads

Cidofovir

Name: Cidofovir
Brand: Adooq Bioscience
SKU: A10214
Availability: InStock
Rating: 5 (1 reviews)

Cat. No. A10214 CAS 113852-37-2

DNA/RNA Synthesis inhibitor

Cidofovir (Vistide) is an antiviral used for the treatment of cytomegalovirus (CMV) infection (ie: retinitis).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

In Vitro Studies

In keratinocyte models, radiolabeled cidofovir accumulated more in the cellular nucleic acid fraction of carcinoma and immortalized cells than in primary keratinocytes. Active diphosphate levels were similar in primary keratinocytes and HPV-positive tumor cells, arguing against preferential activation as the sole explanation. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cidofovir metabolism and cellular incorporation across keratinocyte models

Cell-based study · SiHa and HeLa cervical carcinoma cells; HaCaT immortalized keratinocytes; primary human keratinocytes (PHKs) [1]

The incorporated fraction was higher in carcinoma and immortalized cells than in PHKs. Active diphosphate levels were not significantly different between PHKs and HPV-positive tumor cells, limiting a preferential-activation explanation.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
Radiolabel in methanol-insoluble cellular nucleic acid fraction, interpreted by the authors as incorporated CDV	pmol per 10^6 cells; mean ± SD SiHa: 18.39 ± 0.54; HeLa: 13.17 ± 1.43; HaCaT: 8.62 ± 1.11; PHKs: 1.96 ± 0.71; two experiments	[1]
Intracellular CDV diphosphate in methanol-soluble fraction	pmol per 10^6 cells; mean ± SD SiHa: 3.50 ± 0.02; HeLa: 2.93 ± 0.08; HaCaT: 1.56 ± 0.01; PHKs: 3.56 ± 0.28; two experiments	[1]

Literature-Reported Treatment Conditions

Treatment concentration: 50 μg/ml final CDV; 10 μCi radiolabeled CDV per flask
Exposure duration: 72 h
Method: Radiolabeled compound incubation; conditions performed in duplicate
Vehicle: Tracer supplied in ethanol/water 1:1; final exposure vehicle proportion not specified
Reported limits: No final vehicle fraction is specified in the retrieved method. Two experiments are reported; duplicate conditions are not independent experiment counts.

Methods and source locations

Compound reported in the paper: Cidofovir; Compound label in the paper: [5-3H]-CDV tracer

Radiotracer metabolism experiment; no potency estimate or clinical selectivity claim.

Table 1 and footnote; Methods: Antiviral compound, Cell cultures, Metabolism study with [5-3H]-CDV; Results: Metabolism and incorporation

Radiolabel in methanol-insoluble cellular nucleic acid fraction, interpreted by the authors as incorporated CDV: [5-3H]-CDV exposure followed by fractionation and scintillation counting — Table 1: Incorporated CDV row and footnote; Methods: Metabolism study with [5-3H]-CDV

Intracellular CDV diphosphate in methanol-soluble fraction: Anion-exchange HPLC and radiometric detection — Table 1: CDVpp row and footnote; Results: Metabolism and incorporation

In Vivo Studies

In a virus-free intracranial U87MG xenograft model, cidofovir monotherapy reduced tumor bioluminescence and prolonged mouse survival relative to vehicle. These findings describe an experimental antitumor effect. [2]

Cidofovir monotherapy in a virus-free intracranial U87MG xenograft

Animal study · Intracranial U87MG human glioblastoma xenografts in female athymic mice, without prior HCMV infection [2]

Cidofovir reduced tumor bioluminescence and prolonged survival relative to vehicle in the virus-free xenograft experiment. This is preclinical antitumor evidence.

Measured endpoints — not treatment concentrations
Endpoint	Reported result	Reference
Tumor bioluminescence, day 29 after implantation	Student’s t-test p value p = 0.002	[2]
Animal survival versus vehicle	Log-rank p value p = 0.005	[2]

Conditions shared by the study groups

Route: Intraperitoneal
Frequency: 3 times weekly
Treatment course: Initiated day 11 after tumor cell implantation; continued until required euthanasia according to animal condition
Vehicle: Sterile saline

Study groups and reported outcomes
Group / dose	Comparator	Observed result	Reference
Cidofovir monotherapy 100 mg/kg	Vehicle-treated mice	Lower tumor bioluminescence at day 29 (p = 0.002) and longer survival (p = 0.005) than vehicle; Figure 5.	[2]

Cidofovir monotherapy: Model: Female athymic nu/nu mice, 5–6 weeks old, bearing intracranial U87MG tumors without prior HCMV infection; Reported limits: Methods give 8–10 animals per treatment group generally, without an exact Figure 5 group-specific n. No exact median survival or numerical effect size extracted from curves.

Methods and source locations

Compound reported in the paper: Cidofovir; Compound label in the paper: CDV

Virus-free tumor xenograft only; no human efficacy or antiviral dose claim.

Figure 5A-B and caption; Results paragraph preceding Figure 5; Methods: Intracranial tumor establishment in athymic mice and Bioluminescence monitoring

Tumor bioluminescence, day 29 after implantation: Bioluminescence imaging; normalized signal comparison with vehicle — Figure 5A image/caption; Figure 3 caption test definition

Animal survival versus vehicle: Survival analysis; euthanasia endpoints described in Methods — Figure 5B image/caption; Figure 3 caption test definition

Cidofovir monotherapy · Figure 5A-B and caption; Results paragraph preceding Figure 5; Methods: Intracranial tumor establishment in athymic mice and Bioluminescence monitoring

Specifications

Manufacturer	Adooq Bioscience
Actions	Inhibitor
CAS Number	113852-37-2
Applications	DNA/RNA Synthesis inhibitor
Formula	C₈H₁₄N₃O₆P
Molecular Weight	279.2
Synonyms	Vistide
SMILES	C1=CN(C(=O)N=C1N)C[C@@H](CO)OCP(=O)(O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

Solvent	Reported Solubility
DMSO	2 mg/mL (7.16 mM)
Water	11 mg/mL (39.4 mM)
Ethanol	Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

[1] De Schutter T, Andrei G, Topalis D, et al. Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage. BMC medical genomics (2013). PMID: 23702334 DOI: 10.1186/1755-8794-6-18 Source material
[2] Hadaczek P, Ozawa T, Soroceanu L, et al. Cidofovir: a novel antitumor agent for glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 24170543 DOI: 10.1158/1078-0432.ccr-13-1121 Source material

Publications

1 publication citing this product

Adhikary A, .et al. , J Phys Chem B, 2015, Sep 3;119(35):11496-505 PMID: 26237072